300 related articles for article (PubMed ID: 15628907)
41. Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer--more common than anticipated.
Järvinen TA; Liu ET
Cytopathology; 2003 Dec; 14(6):309-13. PubMed ID: 14632727
[TBL] [Abstract][Full Text] [Related]
42. TOP2A gene copy number change in breast cancer.
Engstrøm MJ; Ytterhus B; Vatten LJ; Opdahl S; Bofin AM
J Clin Pathol; 2014 May; 67(5):420-5. PubMed ID: 24403186
[TBL] [Abstract][Full Text] [Related]
43. HER-2 and TOP2A coamplification in urinary bladder cancer.
Simon R; Atefy R; Wagner U; Forster T; Fijan A; Bruderer J; Wilber K; Mihatsch MJ; Gasser T; Sauter G
Int J Cancer; 2003 Dec; 107(5):764-72. PubMed ID: 14566826
[TBL] [Abstract][Full Text] [Related]
44. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.
Wang J; Xu B; Yuan P; Zhang P; Li Q; Ma F; Fan Y
Breast Cancer Res Treat; 2012 Sep; 135(2):531-7. PubMed ID: 22864769
[TBL] [Abstract][Full Text] [Related]
45. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
O'Malley FP; Chia S; Tu D; Shepherd LE; Levine MN; Bramwell VH; Andrulis IL; Pritchard KI
J Natl Cancer Inst; 2009 May; 101(9):644-50. PubMed ID: 19401546
[TBL] [Abstract][Full Text] [Related]
46. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.
Tubbs R; Barlow WE; Budd GT; Swain E; Porter P; Gown A; Yeh IT; Sledge G; Shapiro C; Ingle J; Haskell C; Albain KS; Livingston R; Hayes DF
J Clin Oncol; 2009 Aug; 27(24):3881-6. PubMed ID: 19620488
[TBL] [Abstract][Full Text] [Related]
47. Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer.
Durbecq V; Desmed C; Paesmans M; Cardoso F; Di Leo A; Mano M; Rouas G; Leroy JY; Sotiriou C; Piccart M; Larsimont D
Int J Oncol; 2004 Nov; 25(5):1473-9. PubMed ID: 15492841
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer.
Zaczek A; Markiewicz A; Supernat A; Bednarz-Knoll N; Brandt B; Seroczyńska B; Skokowski J; Szade J; Czapiewski P; Biernat W; Wełnicka-Jaśkiewicz M; Jassem J
Pathol Oncol Res; 2012 Oct; 18(4):885-94. PubMed ID: 22426810
[TBL] [Abstract][Full Text] [Related]
49. Detection of C-erb B2 gene amplification in bilharzial associated bladder cancer using fluorescence in situ hybridization.
Aly MS; Khaled HM
Urol Oncol; 2004; 22(6):448-52. PubMed ID: 15610859
[TBL] [Abstract][Full Text] [Related]
50. Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.
Pierceall WE; Sprott KM; Heikkinen T; Heikkila P; Alaparthi L; Aittomaki K; Al-Adhami M; Villegas-Bergazzi V; Meyer JL; Kutok JL; Bartkova J; Bartek J; Nevanlinna H; Weaver DT; Blomqvist C
Hum Pathol; 2012 Sep; 43(9):1363-75. PubMed ID: 22204715
[TBL] [Abstract][Full Text] [Related]
51. Prognostic and predictive value of copy number alterations in invasive breast cancer as determined by multiplex ligation-dependent probe amplification.
Tabarestani S; Ghaderian SM; Rezvani H; Mirfakhraie R; Ebrahimi A; Attarian H; Rafat J; Ghadyani M; Alavi HA; Kamalian N; Rakhsha A; Azargashb E
Cell Oncol (Dordr); 2014 Apr; 37(2):107-18. PubMed ID: 24573687
[TBL] [Abstract][Full Text] [Related]
52. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.
Tanner M; Hollmén M; Junttila TT; Kapanen AI; Tommola S; Soini Y; Helin H; Salo J; Joensuu H; Sihvo E; Elenius K; Isola J
Ann Oncol; 2005 Feb; 16(2):273-8. PubMed ID: 15668283
[TBL] [Abstract][Full Text] [Related]
53. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.
Liang Z; Zeng X; Gao J; Wu S; Wang P; Shi X; Zhang J; Liu T
BMC Cancer; 2008 Dec; 8():363. PubMed ID: 19061514
[TBL] [Abstract][Full Text] [Related]
54. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M;
Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518
[TBL] [Abstract][Full Text] [Related]
55. Her-2/neu status in breast cancer metastases to the central nervous system.
Lear-Kaul KC; Yoon HR; Kleinschmidt-DeMasters BK; McGavran L; Singh M
Arch Pathol Lab Med; 2003 Nov; 127(11):1451-7. PubMed ID: 14567724
[TBL] [Abstract][Full Text] [Related]
56. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression.
Tsuda H; Akiyama F; Terasaki H; Hasegawa T; Kurosumi M; Shimadzu M; Yamamori S; Sakamoto G
Cancer; 2001 Dec; 92(12):2965-74. PubMed ID: 11753973
[TBL] [Abstract][Full Text] [Related]
57. Assessment of topoisomerase II-alpha gene status by dual color chromogenic
Neama RAA; Habib MA; Ali SA; Al-Khafaji AH; Alqanbar MF
Indian J Pathol Microbiol; 2017; 60(4):475-480. PubMed ID: 29323058
[TBL] [Abstract][Full Text] [Related]
58. HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics.
Fasching PA; Weihbrecht S; Haeberle L; Gasparyan A; Villalobos IE; Ma Y; Ekici AB; Wachter DL; Hartmann A; Beckmann MW; Slamon DJ; Press MF
Breast Cancer Res Treat; 2014 May; 145(1):193-203. PubMed ID: 24682655
[TBL] [Abstract][Full Text] [Related]
59. Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer.
Partanen L; Staaf J; Tanner M; Tuominen VJ; Borg Å; Isola J
Genes Chromosomes Cancer; 2012 Sep; 51(9):832-40. PubMed ID: 22585709
[TBL] [Abstract][Full Text] [Related]
60. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis.
Gjerdrum LM; Sorensen BS; Kjeldsen E; Sorensen FB; Nexo E; Hamilton-Dutoit S
J Mol Diagn; 2004 Feb; 6(1):42-51. PubMed ID: 14736826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]